Takeda Pharmaceutical Co. Ltd. purchased a new stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 203,190 shares of the company's stock, valued at approximately $278,000. Rani Therapeutics makes up approximately 1.0% of Takeda Pharmaceutical Co. Ltd.'s investment portfolio, making the stock its 10th biggest holding. Takeda Pharmaceutical Co. Ltd. owned approximately 0.35% of Rani Therapeutics at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in RANI. Stifel Financial Corp grew its stake in Rani Therapeutics by 100.4% in the 3rd quarter. Stifel Financial Corp now owns 269,768 shares of the company's stock valued at $583,000 after buying an additional 135,148 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Rani Therapeutics by 14.3% during the third quarter. Geode Capital Management LLC now owns 172,261 shares of the company's stock worth $372,000 after purchasing an additional 21,527 shares during the period. Virtu Financial LLC acquired a new stake in Rani Therapeutics during the 4th quarter worth approximately $62,000. Finally, Janney Montgomery Scott LLC acquired a new position in Rani Therapeutics in the 4th quarter valued at $37,000. 30.19% of the stock is currently owned by institutional investors and hedge funds.
Rani Therapeutics Price Performance
Shares of Rani Therapeutics stock traded down $0.10 on Monday, reaching $1.27. 144,344 shares of the stock were exchanged, compared to its average volume of 899,198. The firm's 50 day moving average is $1.51 and its 200-day moving average is $1.83. The firm has a market cap of $72.47 million, a PE ratio of -1.19 and a beta of 0.14. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60. Rani Therapeutics Holdings, Inc. has a one year low of $1.24 and a one year high of $8.75.
Analyst Upgrades and Downgrades
RANI has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Rani Therapeutics in a research report on Friday, February 7th. Canaccord Genuity Group restated a "buy" rating and set a $9.00 target price on shares of Rani Therapeutics in a research report on Wednesday, February 26th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Rani Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $12.33.
Read Our Latest Report on RANI
Rani Therapeutics Profile
(
Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
See Also
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
